Cargando…

Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy

BACKGROUND & AIMS: Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare liver disease caused by biallelic variations in ABCB4. Data reporting on the impact of genotype and of response to ursodeoxycholic acid (UDCA) therapy on long-term outcomes are scarce. METHODS: We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzales, Emmanuel, Gardin, Antoine, Almes, Marion, Darmellah-Remil, Amaria, Seguin, Hanh, Mussini, Charlotte, Franchi-Abella, Stéphanie, Duché, Mathieu, Ackermann, Oanez, Thébaut, Alice, Habes, Dalila, Hermeziu, Bogdan, Lapalus, Martine, Falguières, Thomas, Combal, Jean-Philippe, Benichou, Bernard, Valero, Sonia, Davit-Spraul, Anne, Jacquemin, Emmanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494458/ https://www.ncbi.nlm.nih.gov/pubmed/37701337 http://dx.doi.org/10.1016/j.jhepr.2023.100844

Ejemplares similares

JAG1 and THBS2 Mutations in a Child Presenting With Incomplete Alagille Syndrome
por: Almes, Marion, et al.
Publicado: (2023)

In vitro functional rescue by ivacaftor of an ABCB11 variant involved in PFIC2 and intrahepatic cholestasis of pregnancy
por: Mareux, Elodie, et al.
Publicado: (2021)

Progressive familial intrahepatic cholestasis
por: Davit-Spraul, Anne, et al.
Publicado: (2009)

In Vitro Rescue of the Bile Acid Transport Function of ABCB11 Variants by CFTR Potentiators
por: Mareux, Elodie, et al.
Publicado: (2022)

Cholestasis Reveals Severe Cortisol Deficiency in Neonatal Pituitary Stalk Interruption Syndrome
por: Mauvais, Francois-Xavier, et al.
Publicado: (2016)

Molecular Regulation of Canalicular ABC Transporters
por: Ben Saad, Amel, et al.
Publicado: (2021)

Targeted-Capture Next-Generation Sequencing in Diagnosis Approach of Pediatric Cholestasis
por: Almes, Marion, et al.
Publicado: (2022)

Type 3 of progressive familial intrahepatic cholestasis (PFIC‐3): Case report
por: Almoshantaf, Mohammad Badr, et al.
Publicado: (2023)

Bile composition in Alagille Syndrome and PFIC patients having Partial External Biliary Diversion
por: Emerick, Karan M, et al.
Publicado: (2008)

A Diagnostic Quagmire: PFIC5 Presenting as a Rare Cause of Neonatal Cholestasis
por: Giang, Sophia, et al.
Publicado: (2021)

RAB10 Interacts with ABCB4 and Regulates Its Intracellular Traffic
por: Ben Saad, Amel, et al.
Publicado: (2021)

Cholic acid for primary bile acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood
por: Gonzales, Emmanuel, et al.
Publicado: (2018)

A Comprehensive Review of Progressive Familial Intrahepatic Cholestasis (PFIC): Genetic Disorders of Hepatocanalicular Transporters
por: Amer, Syed, et al.
Publicado: (2014)

Progressive Familial Intrahepatic Cholestasis (PFIC) Type 3 in Two Sicilian Siblings of Nonconsanguineous Parents
por: Crupi, Isodiana
Publicado: (2010)

Neonatal-onset Progressive Familial Intrahepatic Cholestasis (PFIC): first molecular study in Tunisian patients
por: Selmi, Ines, et al.
Publicado: (2021)

Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study
por: Loomes, Kathleen M., et al.
Publicado: (2022)

Changes in plasma bile acid profiles after partial internal biliary diversion in PFIC2 patients
por: Liu, Teng, et al.
Publicado: (2020)

Advanced Microscopy for Liver and Gut Ultrastructural Pathology in Patients with MVID and PFIC Caused by MYO5B Mutations
por: Hess, Michael W., et al.
Publicado: (2021)

Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation
por: Schumacher, Jonas, et al.
Publicado: (2021)

Biological synthesis of ursodeoxycholic acid
por: Song, Peng, et al.
Publicado: (2023)

Ursodeoxycholic Acid Improves Bilirubin but Not Albumin in Primary Biliary Cirrhosis: Further Evidence for Nonefficacy
por: Tsochatzis, Emmanuel A., et al.
Publicado: (2013)

Effect of Ursodeoxycholic Acid Alone and Ursodeoxycholic Acid Plus Domperidone on Radiolucent Gallstones and Gallbladder Contractility in Humans
por: Tuncer, Ilyas, et al.
Publicado: (2012)

The Conservative Management of Choledocholithiasis With Ursodeoxycholic Acid
por: Oluboyede, Daniel O, et al.
Publicado: (2023)

Molecular Mechanisms of Ursodeoxycholic Acid Toxicity & Side Effects: Ursodeoxycholic Acid Freezes Regeneration & Induces Hibernation Mode
por: Kotb, Magd A.
Publicado: (2012)

Ursodeoxycholic acid production by Gibberella zeae mutants
por: Kollerov, Vyacheslav, et al.
Publicado: (2022)

Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(−/−) mouse model of PFIC3
por: Wei, Guangyan, et al.
Publicado: (2020)

Clinical and genetic characterization of pediatric patients with progressive familial intrahepatic cholestasis type 3 (PFIC3): identification of 14 novel ABCB4 variants and review of the literatures
por: Chen, Rong, et al.
Publicado: (2022)

Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects
por: Murakami, Masanori, et al.
Publicado: (2013)

Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review
por: Li, Xuan, et al.
Publicado: (2020)

Seasonality and growth in tropical freshwater ectotherm vertebrates: Results from 1‐year experimentation in the African gray bichir, giraffe catfish, and the West African mud turtle
por: Gardin, Axelle, et al.
Publicado: (2023)

Ursodeoxycholic acid treatment in a rat model of cancer cachexia
por: Tschirner, Anika, et al.
Publicado: (2011)

Effect of ursodeoxycholic acid on experimental hepatic porphyria induced by griseofulvin.
por: Choi, S. W., et al.
Publicado: (1991)

Ursodeoxycholic Acid Ameliorates Fructose-Induced Metabolic Syndrome in Rats
por: Mahmoud, Amr A. A., et al.
Publicado: (2014)

Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis
por: Torisu, Yuichi, et al.
Publicado: (2017)

Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development
por: Pearson, Talima, et al.
Publicado: (2019)

Reductive effect of ursodeoxycholic acid on bilirubin levels in neonates on phototherapy
por: Ughasoro, Maduka Donatus, et al.
Publicado: (2019)

Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice
por: Oh, Ah-Reum, et al.
Publicado: (2016)

Ursodeoxycholic acid attenuates the expression of proinflammatory cytokines in periodontal cells
por: Talebian, Reza, et al.
Publicado: (2020)

Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients
por: Subramanian, Subbaya, et al.
Publicado: (2020)

Potential effects of ursodeoxycholic acid on accelerating cutaneous wound healing
por: El-Hamoly, Tarek, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e9c5tcvg7mgfp5036t0godvblb